Be part of the knowledge.™

CME/CE

Your professional development is critical to the care of your patients. Stay on top of the latest treatments and information with ReachMD's CME activities. Our topics span cardiology, diabetes, oncology, women's health and more. And our CME library is continuously growing, every quarter.

3607

LikeLikedUnlike

91-105 of 959

Advancing Care in HNSCC: Evolving Strategies Across the Disease Continuum
CME/CE
Advancing Care in HNSCC: Evolving Strategies Across the Disease Continuum
- Kevin J Harrington, PhD, FRCP, FRCR, FRSB
  Peer
- Cristina Rodriguez, MD
  Peer
0.50 credits
From Late-Line Rescue to Early-Line Option: The Potential for Bispecific Antibodies in Multiple Myeloma
CME/CE
From Late-Line Rescue to Early-Line Option: The Potential for Bispecific Antibodies in Multiple Myeloma
- María-Victoria Mateos, MD, PhD
  Peer
- Luciano Costa, M.D., Ph.D.
  Peer
0.25 credits
MinuteCE®
The New Era of RAS Targeting: Mechanisms, Evidence, and Clinical Integration of ON-State Inhibitors
- Kathryn Arbour
  Peer
- Eileen M. O'Reilly, MD
  Peer
0.75 credits 8 episodes
RAS Across Tumors: Who to Test When
MinuteCE®
RAS Across Tumors: Who to Test When
- Kathryn Arbour
  Peer
- Eileen M. O'Reilly, MD
  Peer
0.75 program credits
Unmet Need: Second-Line Outcomes Remain Poor for NSCLC and Pancreatic Cancer
MinuteCE®
Unmet Need: Second-Line Outcomes Remain Poor for NSCLC and Pancreatic Cancer
- Kathryn Arbour
  Peer
- Eileen M. O'Reilly, MD
  Peer
0.75 program credits
Early Approaches to RAS Targeting: Efficacy Signals and Known Limitations
MinuteCE®
Early Approaches to RAS Targeting: Efficacy Signals and Known Limitations
- Kathryn Arbour
  Peer
- Eileen M. O'Reilly, MD
  Peer
0.75 program credits
advertisement
Mechanistic Evolution in RAS Therapy: ON-State and Multi-Selective Targeting
MinuteCE®
Mechanistic Evolution in RAS Therapy: ON-State and Multi-Selective Targeting
- Kathryn Arbour
  Peer
- Eileen M. O'Reilly, MD
  Peer
0.75 program credits
NSCLC Data Review: Efficacy and Safety Data for ON-State RAS Inhibitors
MinuteCE®
NSCLC Data Review: Efficacy and Safety Data for ON-State RAS Inhibitors
- Kathryn Arbour
  Peer
0.75 program credits
Evaluating Use in Pancreatic Cancer: Efficacy and Safety Data for ON-State RAS Inhibitors 
MinuteCE®
Evaluating Use in Pancreatic Cancer: Efficacy and Safety Data for ON-State RAS Inhibitors 
- Eileen M. O'Reilly, MD
  Peer
0.75 program credits
Novel RAS-Targeted Therapy: Prevention, Monitoring, and Mitigation of Adverse Events
MinuteCE®
Novel RAS-Targeted Therapy: Prevention, Monitoring, and Mitigation of Adverse Events
- Eileen M. O'Reilly, MD
  Peer
- Kathryn Arbour
  Peer
0.75 program credits
RAS(ON) and Beyond: Clinical Integration and Strategic Sequencing
MinuteCE®
RAS(ON) and Beyond: Clinical Integration and Strategic Sequencing
- Kathryn Arbour
  Peer
- Eileen M. O'Reilly, MD
  Peer
0.75 program credits
From Pixels to Practice: Advancing HCM Care With Multimodality Imaging
CME/CE
From Pixels to Practice: Advancing HCM Care With Multimodality Imaging
- Marc Dweck, BSc, MBChB, PhD, FRCP, FRSE
  Peer
- Tomaž Podlesnikar, MD, PhD
  Peer
- Jeanette Schulz-Menger, MD
  Peer
0.75 credits
advertisement
Frontline Insights: Emerging Therapeutic Strategies in HNSCC
CME/CE
Frontline Insights: Emerging Therapeutic Strategies in HNSCC
- Kevin J Harrington, PhD, FRCP, FRCR, FRSB
  Peer
- Christophe Le Tourneau, MD, PhD
  Peer
0.25 credits
Breaking the Line: Moving Bispecific Antibodies Upstream in Treating Multiple Myeloma
CME/CE
Breaking the Line: Moving Bispecific Antibodies Upstream in Treating Multiple Myeloma
- María-Victoria Mateos, MD, PhD
  Peer
0.25 credits
No Patient with CKD Left Behind! Emerging CKD Therapies in T1D
CME/CE
No Patient with CKD Left Behind! Emerging CKD Therapies in T1D
- Richard E. Pratley, MD
  Peer
- David Cherney, MD, PhD
  Peer
- prof. Hiddo Heerspink
  Peer
0.50 credits

Program Chapters

Segment Chapters

Playlist:

Recommended